1Bellamy N,Buchanan WW,Goldsmith CH,et al. Validation study of Womac:a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee.J Rheumatol, 1988,
2Warner TD,Giuliano F,Vojnovic I,et al. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity:a full in vitro analysis. Proc Natl Acad Sci USA, 1996,12:7563-7568.
3Cannon GW,Caldwell JR,Holt P,et al. Rofecoxib,a specific inhibitor of cyclooxygenase 2,with clinical efficacy comparable with that of diclofenac sodium:results of a one-year,randomized,clinical trial in patients with osteoarthritis of the knee and hip. Ar
4Gordon S,Morrison C.Fibromyalgia and its primary care implications.Med Surg Nursing, 1998,7:207-216.
5Miura T,Asai T,Sato K,et al. Effects of Myonal on disease associated with pain in the field of orthopedics surgery.Jpn J Clin Med, 1987,64:1641-1648.
6Matsunaga M,Uemura Y,Dehn TC,et al.Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats. Jpn J Pharmacol, 1997,73:215-220.
7Altman RD.Classification of disease:osteoarthritis. Semin Arthritis Rheum, 1991,20(Suppl 2):40-47.
8Kellgren JH,Lawrence JS.Radiological assessment of osteoarthritis. Ann Rheum Dis,1957,16:494-502.
9Geba GP.Efficacy of rofecoxib,celecoxib,and acetaminophen in osteoarthritis of the knee:a randomized trial. JAMA,2002,287:64-71.
10Block JA,Schnitzer TJ.Therapeutic approaches to osteoarthritis. Hosp Pract, 1997,32:159-164.
